Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK

Overview of attention for article published in PharmacoEconomics, September 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

policy: 2 policy sources

Citations

dimensions_citation: 71 Dimensions

Readers on

mendeley: 72 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 8 policy documents that reference this research output.

risankizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 16 Aug 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 13 Dec 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Vedolizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Dec 2018

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer: Committee papers

Cited by National Institute for Health and Care Excellence on 09 Nov 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer: Committee papers

Cited by National Institute for Health and Care Excellence on 25 Aug 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Ustekinumab for moderately to severely active Crohn’s disease after previous treatment : Committee papers

Cited by National Institute for Health and Care Excellence on 20 Apr 2017

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Advanced breast cancer: diagnosis and treatment : Evidence review

Cited by National Institute for Health and Care Excellence on 19 Dec 2011

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Advanced breast cancer: diagnosis and treatment : Full guideline

Cited by National Institute for Health and Care Excellence on 20 Feb 2009

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.